Fig. 3.

IP-10/IL-17 co-treatment induces OPN, OCN and ALP expressions in HCASMCs. The HCASMCs were maintained either as controls or were treated with IP-10, IL-17, or both, for 3, 7, or 10 days, after which we examined the mRNA expressions of OPN (a), OCN (b), and ALP (c) using real-time PCR and the protein expressions of OPN, OCN, and ALP (d–e) using the western blot test. The data in (a–e) are mean ± SEM from three independent experiments. * P < 0.05 vs. control cells. The results in (d–e) are representative of three independent experiments with similar results